Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019052 | Depression, Postpartum NIH | 0.33 |
| D003863 | Depression, NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Some patients infected with COVID-19 require hospitalisation and develop patients a severe form of a lung disease called respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus. The inflammation causes fluid from nearby blood vessels to leak into the tiny air sacs in the lungs, making breathing increasingly difficult. This fluid forms small clots in the air sacs, creating a barrier until the cells regenerate. In some patients, this clot does not disappear in a timely fashion or interferes with the development of the new cells. Furthermore, the small clots in the air sacs obstruct the air and oxygen getting deep into the lungs, interfering with proper ventilation. The trial will recruit patients with COVID-19 induced ARDS. Eligible patients (or if patients lack capacity, their legal representative) will be provided with an information sheet and informed consent will be sought. Eligibility will be mainly assessed via routine clinical assessments. Patients will receive a nebulised version of a type of drug called tissue plasminogen activator (rt-PA) that is inhaled using a nebuliser. This is normally a drug used to break down blood clots. In this situation though, it might be useful for stopping clots forming in the lungs, because these might lead to even more difficulties with breathing. The first 12 consented patients will receive nebulised rt-PA in addition to standard of care (SOC). The second group of 12 patients will receive SOC alone as a comparison. To evaluate efficacy, the improvement of oxygen levels over time and safety will be be monitored throughout. Blood samples will be taken to measure markers of clotting and inflammation in both groups. From the end of the treatment phase (after Day 3) both groups will be followed up in accordance with SOC.
Description: Percentage change in PaO2/FiO2 ratio from baseline and to day 5 (96 hrs ± 2 hrs) post treatment and day 7 (144 hrs ± 4hrs) in the groups receiving rt-PA
Measure: treatment efficacy - Percentage change in PaO2/FiO2 ratio Time: 144 hoursDescription: Incidence and severity of major bleeding events
Measure: Safety as measured by bleeds Time: 28 daysDescription: Incidence and severity of adverse events More than 1 treatment-emergent serious adverse event (SAE) during and up to 24 hours of the treatment
Measure: Safety as measured by other (non-bleed related) adverse events Time: 28 daysDescription: Decrease in fibrinogen levels over 72 hrs post initiation of treatment (>50%).
Measure: Safety as measured by fibrinogen levels Time: 72 hoursDescription: Absolute change in PaO2/FiO2 ratio post treatment assessed at day 5 (96 hrs ± 2 hrs) and day 7 (144 hrs ± 4hrs)
Measure: Absolute change in PaO2/FiO2 ratio Time: 7 daysDescription: Changes in respiratory compliance from baseline and absolute values at day 5 (96 hrs ± 2 hrs) and day 7 (144 hrs ± 4hrs), as measured by PIP (Peak inspiratory pressure) minus PEEP (Positive end-expiratory pressure) at each timepoint
Measure: Changes in respiratory compliance Time: 7 daysDescription: Clinical status as assessed by a 7-point WHO ordinal scale at baseline and daily up to day 7. Points on the scale are: Death Hospitalized, on invasive mechanical ventilation or ECMO Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring low flow supplemental oxygen Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Not hospitalized
Measure: Clinical status as determined by a 7 point ordinal scale Time: 7 daysDescription: Mean daily Sequential Organ Failure Assessment (SOFA) score at baseline through up to day 7 (done daily)
Measure: Sequential Organ Failure Assessment (SOFA) score Time: 7 daysDescription: Duration of oxygenation free days, up to 28 days or death or discharge, whichever occurs first.
Measure: Follow up period - oxygen free days Time: 28 daysDescription: In follow up period, ventilator free days, up to 28 days or death or discharge, whichever occurs first.
Measure: Follow up period - ventilator free days Time: 28 daysDescription: In follow up period, intensive care stay, up to 28 days or death or discharge, whichever occurs first.
Measure: Follow up period - intensive care stay Time: 28 daysDescription: Incidence of either new oxygen use via ventilation in the first 28 days. These include non-invasive ventilation or high flow oxygen devices
Measure: New oxygen via ventilation use - incidence Time: 28 daysDescription: Total duration of new oxygen use via ventilation in the first 28 days. These include non-invasive ventilation or high flow oxygen devices.
Measure: New oxygen via ventilation use - duration Time: 28 daysDescription: Incidence of new mechanical ventilation use during in the first 28 days
Measure: Incidence of new mechanical ventilation use Time: 28 daysDescription: Duration of new mechanical ventilation use during in the first 28 days
Measure: Duration of new mechanical ventilation use Time: 28 daysDescription: In hospital mortality
Measure: In hospital mortality Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports